Research by NMIN research leader Dr. Marcel Bally and team at Cuprous Pharmaceuticals is featured on the cover of the February 2020 issue of Drug Delivery and Translational Research.
The article, Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use, discusses the benefits brought to quercetin by Cuprous’ Metaplex technology platform—a platform that can be applied to any number of therapeutics in diverse fields.
“Although quercetin, a flavonoid commonly found in fruits and vegetables, has potential anticancer effects, it has had limited clinical utility to date because of its poor solubility,” comments Dr. Bally.
“Now, however, as detailed in this article, our team at Cuprous has successfully addressed these solubility issues using a novel liposomal formulation of copper-quercetin, generated through our Metaplex platform.”